30 closest matches · ranked by relevance
Healthy Volunteers
Primary: Levodopa Area Under the Concentration-time Curve From Time 0 to the 24 h PK Sample (AUC0-24) Time 0 to the 24 h PK Sample (AUC0-24) — 4300; 5423; 7439; 9046 h*ng/ml
Genetic Disease · Nonsense Mutation
Primary: Pharmacokinetic Parameters - Plasma AUC0-24 — 1105.126; 3125.484; 11018.22; 28235.823 ng*h/mL
Inflammatory Bowel Diseases
Primary: Safety Indicators：Adverse Event — 1; 3; 2; 3 Participants
Not Determined
Primary: Evaluation of Frequency, Seriousness and Intensity of Adverse Events — 7; 1; 3; 4 Adverse events
Healthy Volunteers
Primary: Adverse Events — 0; 2; 3; 3 Participants
Alzheimer Disease, Early Onset · Alzheimer Disease
Primary: Maximum Plasma Concentration (Cmax) — 315; NA; 550; NA ng/mL
Healthy Participants
Primary: Incidence of Treatment Emergent Adverse Events — 2; 2; 0; 3 participants
Malaria
Primary: Number of Participants With Adverse Events — 4; 5; 5; 6 Participants
Tuberculosis
Primary: Incidence of Drug-related Adverse Events [Safety and Tolerability] — 2; 2; 1; 0 participants
Smoking Cessation
Primary: Number of Adverse Events — 5; 0; 1; 1 Participants
Ascites Hepatic
Primary: Incidence of Treatment-Emergent Adverse Events — 1; 0; 2; 1 Participants
SARS-CoV-2 Infection
Primary: Preliminary Safety and Tolerability of CT-P59 — 0; 2; 1; 0 Participants
Healthy
Primary: Number of Participants With Categorical Scores on the Columbia Suicide Severity Rating Scale (C-SSRS) Post-Baseline — 0; 0; 0; 0 participants
Not Applicable as This is a Mass Balance/Pharmacokinetic Study Performed in Healthy Subjects · Apathy
Primary: Determination of Maximum Plasma Concentration [Cmax] of IRL757 — 2.88; 11.42 μmol/L
Breast Cancer
Primary: Pharmacokinetics: Maximum Plasma Concentration (Cmax) for AZD9496 and Its Metabolites at Each Treatment Period. — 64.85; 381.0; 138.2; 91.83 ng/mL
Safety · Pharmacokinetics · Healthy Subjects
Primary: Pharmacokinetics: Observed Maximum Serum Concentration (Cmax) Following Single Dose of Anifrolumab. — 36.22; 82.44; 63.86 ug/mL
Safety Issues · Tolerance
Primary: Percentage of Participants Reporting at Least One Treatment-emergent Adverse Event (TEAE) — 50.0; 33.3; 83.3; 16.7 Percentage of participants
Coronavirus
Primary: Part 1: Number of Participants With Treatment Emergent Adverse Events and Severity of Treatment Emergent Adverse Events — 7; 2; 0; 3 Participants
Safety · Healthy Subjects
Primary: Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Treatment-emergent Serious Adverse Events (TESAEs) — 8; 4; 2; 5 Participants
Healthy Male Subjects · Cardiovascular Disease
Primary: Safety and Tolerability of AZD5718 by Assessment of the Number of Participants With Adverse Events Following Oral Administration of SAD (Part A) and MAD (Part B). — 15…
Healthy Volunteer Study · Opioid-use Disorder
Primary: Proportion of Participants With TEAEs — 1; 1; 2; 0 Participants
Hepatitis B
Primary: Number of Participants With Any Non-serious Adverse Event (AE); Any Serious AE (SAE); Any AEs Leading to Discontinuation of Study Treatment (AELD) in Part 1 — 4; 3; 2; 3…
Healthy Volunteers
Primary: Percentage of Participants Who Have at Least One Treatment-Emergent Adverse Event (TEAE) — 0; 50.0; 16.7; 0 percentage of participants
Alzheimer's Disease
Primary: Number of Participants With Clinically Significant Effects (Adverse Events) — 0; 0; 0; 0 Participants
Health, Subjective
Primary: Incidence Rate of Drug Allergy Following ID Injection of the IP — 0; 0; 1; 0 Participants
Chikungunya Virus Infection
Primary: Frequency of Adverse Events (AEs) — 5; 3; 2; 3 Participants
Influenza A
Primary: Part 1 SAD: Number of Participants With Treatment-Emergent Adverse Events (TEAE) — 3; 3; 6; 4 Participants
Safety Issues
Primary: Characterize the Safety and Tolerability of EXT608 — 2; 2; 0; 0 Participants
Pharmacodynamics · Healthy Subjects
Primary: Pharmacodynamics of AZD9977 Assessed Per Sodium/Potassium Ratio in Urine in Eplerenone Treatment Versus a Combination Treatment of Eplerenone and AZD9977. — -0.545…
Multiple Sclerosis · Colitis, Ulcerative
Primary: Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs) — 8; 3; 2; 6 Participants